FindTrial
Sign In

Intravitreal injection of Bevacizumab (Avastin) as an adjunctive therapy of pterygium surgery to prevent recurrence: A pilot study

Intravitreal injection of Bevacizumab (Avastin) as an adjunctive therapy of pterygium surgery to prevent recurrence: A pilot study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-08000714
Enrollment
Unknown
Registered
2008-02-15
Start date
2008-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pterygium

Interventions

One cohort:Intravitreal injection of Bevacizumab (Avastin?) after surgical excision of pterygium immediately

Sponsors

None listed

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age 18 years or above; 2. Eye with single-head primary or secondary pterygium; 3. Patient able and willing to give informed consent to the pterygium surgery with intravitreal injections of bevacizumab

Exclusion criteria

Exclusion criteria: 1. Single functional eye; 2. Pregnant patients; 3. Use of anticoagulants or antiplatelet therapy other than aspirin / NSAID within 14 days of surgery.

Design outcomes

Primary

MeasureTime frame
Recurrence of pterygium, up to 24 months post op;—

Secondary

MeasureTime frame
- Visual acuity (VA) - Intraocular pressure (IOP) - Corneal endothelial cell counts - Corneal astigmatism - Any complications from the injections;—

Countries

China

Contacts

Public ContactProf. Dennis SC Lam
dennislam_cu_res@cuhk.edu.hk+852 27623134

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026